GlassScriptPhysician profile
Allison N Osen
NPI 1528597945
$6,274.16
in general payments reported to CMS, 2019-2025
31 companies · $784 in 2025
The $784 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $134 · 2022: $147 · 2023: $1,726 · 2024: $3,359 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,712 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,712.31 |
| Education | $157.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,166.42 | 2023-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $912.17 | 2023-2025 | |
| Biogen, INC. | $744.34 | 2022-2025 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $402.36 | 2019-2024 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $389.40 | 2023-2024 | |
| Ucb, INC. | $296.69 | 2023-2024 | Briviact, Rystiggo |
| Abbvie INC. | $278.44 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $272.67 | 2024 | Qelbree |
| Genzyme Corporation | $241.74 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $207.02 | 2023-2024 | Zeposia |
| Celgene Corporation | $174.90 | 2023-2024 | Zeposia |
| Sk Life Science, INC. | $143.44 | 2023-2024 | |
| Lilly USA, LLC | $140.51 | 2023-2024 | Amyvid, Reyvow, Emgality |
| Catalyst Pharmaceuticals, INC. | $127.06 | 2023-2024 | Firdapse |
| Mdd US Operations, LLC | $93.24 | 2024 | Apokyn |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $88.58 | 2023-2024 | Austedo Xr |
| Eisai INC. | $73.60 | 2023-2024 | |
| Livanova USA, INC. | $56.78 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Otsuka America Pharmaceutical, INC. | $56.08 | 2023-2024 | Nuedexta |
| Acadia Pharmaceuticals INC | $55.47 | 2023-2024 | Nuplazid |
| Argenx US, INC. | $54.98 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $54.17 | 2023-2024 | Vyepti |
| Grifols USA, LLC | $43.25 | 2023-2024 | Gamunex-C |
| Acorda Therapeutics, INC | $42.94 | 2023 | Ampyra, Inbrija |
| Pfizer INC. | $41.92 | 2024 | |
| Banner Life Sciences, LLC | $25.52 | 2024 | |
| Amgen INC. | $22.90 | 2024 | Uplizna |
| Csl Behring | $21.91 | 2024 | Hizentra |
| Boston Scientific Corporation | $16.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.67 | 2023 | |
| Aucta Pharmaceuticals, INC. | $13.61 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Osen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.